Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05005728 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | PHASE2 | COMPLETED | 72 | — | — | Oct 22, 2021 | Jun 10, 2025 | May 5, 2026 | 26 | United States |
| Arm | Type | Description |
|---|---|---|
| Cohort A - AVPCa | EXPERIMENTAL | - |
| Cohort B - HRD/CDK12 PARP - Progressors | EXPERIMENTAL | - |
| Cohort C - HRD/CDK12 PARP Naïve | EXPERIMENTAL | - |
| Cohort D - MSI-H, MMRD or TMB-H | EXPERIMENTAL | - |
| Cohort E - No Targetable Mutations | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| vudalimab + carboplatin + cabazitaxel | COMBINATION_PRODUCT | Vudalimab IV, carboplatin IV, cabazitaxel IV |
| vudalimab + olaparib | COMBINATION_PRODUCT | Vudalimab IV, olaparib oral |
| vudalimab monotherapy | BIOLOGICAL | Vudalimab IV |
| vudalimab + docetaxel | COMBINATION_PRODUCT | Vudalimab IV, docetaxel IV |
| vudalimab + cabazitaxel or docetaxel | COMBINATION_PRODUCT | Vudalimab IV, cabazitaxel or docetaxel IV |
Inclusion Criteria: * Able to provide written informed consent * Adult (age ≥ 18 years) * Histologically confirmed diagnosis of carcinoma of the prostate * Documented progressive mCRPC based on at least one of the following criteria: * PSA progression, defined as at least 2 rises in PSA with a m...